Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,565.00
0.00 (0.00%)
Aug 11, 2026, 1:30 PM KST

Bukwang Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
200,684200,714160,087125,928190,909182,491
Revenue Growth
15.67%25.38%27.13%-34.04%4.61%7.56%
Gross Profit
89,66491,52874,06446,91679,14775,550
Operating Income
12,25414,1641,618-37,497-230.645,622
Net Income
13,80412,558-2,641-31,330-2,475-916.62
Earnings Per Share
153.39152.01-39.00-458.00-36.15-13.39
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Pharmaceutical
190,771191,394162,684129,486196,932182,491
Research and Development Department
-10,692----
Consolidation Adjustments
-1,232-1,371-2,597-3,557-6,023-
Total
200,684200,714160,087125,928190,909182,491

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
209,423216,208130,091151,22785,51784,277
Total Debt
80,65480,34179,42479,387930.791,558
Net Cash (Debt)
128,769135,86750,66771,84084,58682,719
Net Cash Growth
144.55%168.16%-29.47%-15.07%2.26%21.57%
Net Cash Per Share
1430.881644.73748.111049.461235.651208.27

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
12,72921,46434,362-9,36216,46126,525
Capital Expenditures
-7,685-7,257-1,938-2,835-4,298-785.05
Free Cash Flow
5,04414,20632,424-12,19612,16325,740
Free Cash Flow Growth
-79.77%-56.18%---52.74%-

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
44.68%45.60%46.27%37.26%41.46%41.40%
Operating Margin
6.11%7.06%1.01%-29.78%-0.12%3.08%
Pretax Margin
4.38%3.18%-1.85%-31.42%-0.54%2.08%
Profit Margin
6.88%6.26%-1.65%-24.88%-1.30%-0.50%
FCF Margin
2.51%7.08%20.25%-9.69%6.37%14.11%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
29.7629.74----
Forward PE
-58.7558.7558.7558.7558.75
P/FCF Ratio
89.3026.299.69-49.2534.31
PS Ratio
2.241.861.963.323.144.84